Palisade Bio Announces Enrollment and Dosing of First Patient in LB1148 Dose Optimization Study

May 11, 2023

https://www.globenewswire.com/news-release/2023/05/11/2666817/0/en/Palisade-Bio-Announces-Enrollment-and-Dosing-of-First-Patient-in-LB1148-Dose-Optimization-Study.html

Study designed to determine if a different dosing protocol for all indications might enhance the risk profile of LB1148 while simultaneously providing efficacy

Read more at globenewswire.com

Related news for (PALI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.